Back to Journals » Drug Design, Development and Therapy » Volume 13

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy

Authors Cotter TG, Jensen DM

Received 26 November 2018

Accepted for publication 27 June 2019

Published 29 July 2019 Volume 2019:13 Pages 2565—2577


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Frank M. Boeckler

Thomas G Cotter,1 Donald M Jensen2

1Center for Liver Diseases, The University of Chicago Medicine, Chicago, IL, USA; 2Section of Hepatology, RUSH University Medical Center, Chicago, IL, USA

Abstract: Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, have addressed many of the existing shortcomings in the DAA therapy spectrum. This combination has proven to be a highly efficacious pan-genotypic DAA with a high barrier to resistance as a once-daily, all-oral medication. This review explores the design and development of glecaprevir and pibrentasvir, its place in current HCV management in the midst of a myriad of DAA therapy options, and also remaining challenges.

Keywords: glecaprevir, pibrentasvir, direct-acting antiviral therapy, hepatitis C virus

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]